![]() |
市場調查報告書
商品編碼
1378843
細胞計數市場:2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測Cell Counting Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年全球細胞計數市場規模達到104億美元。展望未來, IMARC Group預計到2028年市場規模將達到155億美元,2022-2028年複合年成長率(CAGR)為6.9%。
細胞計數是指用於分析通常懸浮在血液或其他體液中的細胞或膠束的技術。用於細胞計數的一些常見儀器包括血球計數器、分光光度計、流式細胞儀、自動細胞計數器等。細胞計數有助於對細胞類型進行分類並透過探針檢測疾病,從而為患者制定最佳治療計劃。它還有助於了解細胞的結構和組成,用於染色體分析、蛋白質表現、癌症診斷、血液惡性腫瘤等。因此,細胞計數廣泛應用於醫院、診斷實驗室、研究和學術機構、製藥和生物技術公司等
癌症、愛滋病毒/愛滋病、白血病、阿茲海默症等各種慢性疾病的盛行率不斷上升,推動了對細胞計數技術的需求。此外,分子生物學、免疫學、病理學等不同醫學領域也擴大採用細胞計數儀器來開發下一代療法,這也促進了市場的成長。除此之外,擴大利用細胞計數來識別和測定原發性腫瘤、循環腫瘤和轉移性腫瘤,進一步推動了市場的成長。此外,幹細胞療法的廣泛採用也推動了全球對各種細胞計數儀器的需求。與此一致的是,人們對細胞計數技術在免疫表現型、細胞分選、細胞增殖測定和細胞內鈣通量方面的眾多優勢的認知不斷提高,這進一步推動了市場的成長。此外,多個政府機構對生物技術、腫瘤幹細胞治療等領域廣泛研發活動的投資不斷增加,也促進了細胞計數技術的採用。未來幾年,自動化產品變體的推出將繼續推動全球細胞計數市場的發展,這些產品具有以更高的速度處理更大樣本量的能力。
The global cell counting market size reached US$ 10.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 15.5 Billion by 2028, exhibiting a growth rate (CAGR) of 6.9% during 2022-2028.
Cell counting refers to a technique used for the analysis of the cells or micelles that are usually suspended in blood or other body fluids. Some of the common instruments used for cell counting includes hemocytometers, spectrophotometers, flow cytometers, automated cell counters, etc. Cell counting aids in classifying cell types and detecting disease through probes to develop the best treatment plan for the patient. It also helps in understanding the structure and composition of the cells for chromosome analysis, protein expression, cancer diagnosis, hematological malignancies, etc. As a result, cell counting is extensively used across hospitals, diagnostic laboratories, research and academic institutes, pharmaceutical and biotechnology companies, etc.
The rising prevalence of various chronic ailments, such as cancer, HIV-AIDS, leukemia, Alzheimer's, etc., is propelling the demand for cell counting techniques. Moreover, the growing adoption of cell counting instruments across diverse medical fields, such as molecular biology, immunology, pathology, etc., for developing next-generation therapeutics is also augmenting the market growth. In addition to this, the increasing utilization of cell counting for the identification and determination of primary tumor, circulating tumor, and metastatic tumor is further bolstering the market growth. Additionally, the widespread adoption of stem cell therapy is also propelling the demand for various cell counting instruments on a global level. In line with this, the rising awareness towards numerous benefits of cell counting technique in immunophenotyping, cell sorting, cell proliferation assays and intracellular calcium flux is further driving the market growth. Moreover, the increasing investments by several government bodies in extensive R&D activities pertaining to the fields of biotechnology, oncology stem cell therapeutics, etc., are also bolstering the adoption of cell counting techniques. In the coming years, the introduction of automated product variants with enhanced ability to process larger sample sizes at a higher speed will continue to drive the global market for cell counting.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cell counting market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type and end user.
Consumables
Reagents
Assay Kits
Microplates
Accessories
Instruments
Spectrophotometers
Flow Cytometers
Hematology Analyzers
Cell Counters
Hospitals and Diagnostic Laboratories
Research and Academic Institutes
Pharmaceutical and Biotechnology Companies
Others
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined with some of the key players being Agilent Technologies Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd. (Roche Holding AG)., Merck & Co. Inc., PerkinElmer Inc. and Thermo Fisher Scientific Inc.